Table 2 Clinical and laboratory characteristics of epilepsy patients with diagnosed AE and NSAbs (+)
From: Early predictors of new-onset immune-related seizures: a preliminary study
Age | Sex | NSAbs | APE2 Score | Clinical diagnosis of AE | MRI limbic system | Epilepsy risk factors | Video-EEG epileptiform discharge | Concomitant tumor | ASM | Immunity therapy | mRS | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
On admission | Six months later | |||||||||||
21 | Female | NMDAR | 8 | Yes | Yes | No | No | Ovarian teratoma | 1 | IVMP, IVIg, PL EX,Pred | 4 | 0 |
66 | Male | Not detected | 7 | Yes | No | No | No | No | 2 | IVMP, IVIg | 3 | 1 |
63 | Male | LGI1 | 7 | Yes | Yes | No | No | No | 0 | IVMP,Pred | 3 | 1 |
62 | Male | LGI1 | 7 | Yes | No | No | No | No | 2 | IVDXM | 3 | 1 |
74 | Female | LGI1 | 6 | Yes | No | No | No | No | 2 | IVMP,IVIg,Pred | 3 | 1 |
71 | Male | GABABR | 6 | Yes | Yes | No | No | Lung cancer | 1 | IVMP,Pred | 4 | 6 |
17 | Female | NMDAR | 6 | Yes | No | No | No | Ovarian teratoma | 1 | IVMP,IVIg,PLEX,Pred | 4 | 1 |
16 | Female | NMDAR | 6 | Yes | No | No | No | Ovarian teratoma | 1 | IVMP,IVIg,Pred | 3 | 0 |
71 | Male | LGI1 | 5 | Yes | Yes | No | Yes | No | 1 | IVMP | 3 | 1 |
58 | Male | NMDAR | 5 | Yes | No | No | No | No | 0 | IVMP,Pred | 3 | 1 |
39 | Female | CASPR2 | 5 | Yes | No | No | No | Thymoma | 1 | IVMP,IVIg, Pred | 3 | 0 |
34 | Female | GABABR | 5 | Yes | Yes | No | No | No | 1 | IVMP,IVIg,Pred | 4 | 0 |
55 | Female | GABABR | 4 | Yes | Yes | No | No | No | 1 | IVMP,Pred | 3 | 0 |
49 | Female | LGI1 | 4 | Yes | No | No | No | No | 0 | IVMP,Pred | 4 | 0 |
34 | Male | Not detected | 4 | Yes | No | No | No | No | 1 | IVMP,IVIg, Pred | 3 | 0 |
25 | Female | NMDAR | 4 | Yes | No | No | No | Ovarian teratoma | 1 | IVMP,IVIg,Pred | 3 | 0 |
17 | Female | CASPR2/NMDAR | 4 | Yes | No | No | Yes | No | 0 | IVDXM | 3 | 0 |
74 | Male | CASPR2 | 3 | Yes | No | No | No | No | 1 | IVMP,IVIg, Pred | 3 | 0 |
73 | Male | NMDAR | 3 | Yes | No | No | No | No | 0 | IVMP | 3 | 0 |
72 | Female | NMDAR | 3 | No | No | No | Yes | No | 1 | None | 1 | 1 |
21 | Female | LGI1 | 3 | No | Yes | No | Yes | Ganglioglioma | 1 | None | 1 | 1 |
20 | Male | CASPR2 | 3 | No | No | No | Yes | No | 2 | None | 1 | 1 |
62 | Male | NMDAR | 2 | Yes | No | No | No | No | 1 | IVMP,Pred | 4 | 3 |
55 | Female | NMDAR | 2 | Yes | No | No | No | No | 1 | IVMP,IVIg, Pred | 4 | 2 |
53 | Female | NMDAR | 2 | Yes | No | No | No | No | 0 | IVMP,Pred | 3 | 0 |
32 | Male | CASPR2 | 2 | Yes | No | No | No | No | 1 | IVDXM | 2 | 1 |
72 | Male | LGI1 | 1 | No | No | No | Yes | No | 1 | None | 1 | 0 |
68 | Male | LGI1 | 1 | No | No | No | Yes | No | 1 | None | 1 | 1 |
52 | Male | NMDAR | 1 | No | No | No | Yes | No | 0 | None | 1 | 0 |
36 | Male | NMDAR | 1 | No | No | No | No | No | 1 | None | 1 | 0 |
17 | Female | CASPR2 | 1 | No | No | No | No | No | 1 | None | 1 | 1 |
14 | Male | NMDAR | 1 | No | No | No | Yes | No | 1 | None | 1 | 0 |
10 | Female | NMDAR | 1 | No | No | No | Yes | No | 1 | None | 1 | 0 |
10 | Male | NMDAR | 1 | No | No | No | No | No | 1 | None | 1 | 1 |
8 | Female | GABABR | 1 | No | No | No | Yes | No | 1 | None | 1 | 0 |
2 | Female | NMDAR | 1 | No | No | No | Yes | No | 0 | None | 1 | 1 |